Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1209 single-site vs multiple-site subcutaneous injections in healthy volunteers
NCT06837077Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recaticimab in hypercholesterolemia and hyperlipidemia (2 arms), sponsored by Hengrui. Primary endpoints: Visual Analog Scale for injection site pain (single-site) at 57 days, Visual Analog Scale for injection site pain (multiple-site) at 57 days and 3 more. Started Mar 2025; status: completed.
02
Drugs
recaticimab
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on NCT06837077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837077.